Alterations of β‐tubulin isotypes in breast cancer cells resistant to docetaxel
Open Access
- 31 May 2005
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 19 (10) , 1299-1301
- https://doi.org/10.1096/fj.04-3178fje
Abstract
Docetaxel is one of the most active drugs used to treat breast cancer. The cellular target of docetaxel is the microtubule, specifically the β-tubulin subunit, that comprises a series of isotypes and...Keywords
Funding Information
- Breast Cancer Campaign
This publication has 30 references indexed in Scilit:
- Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With DocetaxelJournal of Clinical Oncology, 2002
- Structural Insights into Microtubule FunctionAnnual Review of Biochemistry, 2000
- Efficacy and safety of docetaxel (Taxotere™) in heavily pretreated advanced breast cancer patientsEuropean Journal Of Cancer, 1999
- Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast GroupEuropean Journal Of Cancer, 1999
- Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere®) in the UKAnnals of Oncology, 1999
- Microtubules and actin filaments: dynamic targets for cancer chemotherapyCurrent Opinion in Cell Biology, 1998
- Structure of the αβ tubulin dimer by electron crystallographyNature, 1998
- Taxol and taxotere—Current status and future prospectsEuropean Journal Of Cancer, 1993
- Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.Proceedings of the National Academy of Sciences, 1993